Our Pipeline

Building a pipeline for advanced therapy medicines

We have a pipeline consisting of programs at different stages of development, within three platforms - cellular, extracellular vesicle therapy, and gene engineering

We target quantifiable medical benefits in multiple inflammatory/ NLRP3 therapeutic areas

PLATFORM

PROGRAM

INDICATIONS

PROOF-OF-CONCEPT

PRE-CLINICAL

IND-ENABLING

CLINICAL

KELI-101

KELI-102

KELI-103

KELI-104

KELI-105

Post-ischaemic acute kidney injury

Moderate to severe acute respiratory distress syndrome

Neutrophilic dermatosis

Cardiorenal syndrome

KELI-100

KELI-200

KELI-201

Extracellular vesicles (undisclosed indication)

KELI-300

KELI-301

Gene-engineering (undisclosed indication)

Symptomatic joint osteoarthritis

PROOF-OF-CONCEPT

PRE-CLINICAL

IND-ENABLING

CLINICAL

KELI-100 Platform

Symptomatic joint osteoarthritis

Post-ischaemic acute kidney injury

Moderate to severe acute respiratory distress syndrome

Neutrophilic dermatosis

Cardiorenal syndrome

KELI-200 Platform

PROOF-OF-CONCEPT

PRE-CLINICAL

IND-ENABLING

CLINICAL

Undisclosed indication (extracellular vesicles)

KELI-300 Platform

PROOF-OF-CONCEPT

PRE-CLINICAL

IND-ENABLING

CLINICAL

Undisclosed indication (gene-engineering)

KELI-101

KELI-102

KELI-103

KELI-104

KELI-105

KELI-201

KELI-301